PLoS ONE (Jan 2018)

Tumor-based gene expression biomarkers to predict survival following curative intent resection for stage I lung adenocarcinoma.

  • Alisson Clemenceau,
  • Nathalie Gaudreault,
  • Cyndi Henry,
  • Paula A Ugalde,
  • Catherine Labbé,
  • Michel Laviolette,
  • Philippe Joubert,
  • Yohan Bossé

DOI
https://doi.org/10.1371/journal.pone.0207513
Journal volume & issue
Vol. 13, no. 11
p. e0207513

Abstract

Read online

BackgroundPrognostic biomarkers are needed in clinical setting to predict outcome after resection for early-stage lung adenocarcinoma. The goal of this study is to validate tumor-based single-gene expression biomarkers with demonstrated prognostic value in order to move them along the clinical translation pipeline.MethodsPrognostic genes were selected from the literature and the best candidates measured by quantitative real-time polymerase chain reaction (qPCR) in tumors of 233 patients with stage I adenocarcinoma. Significant prognostic genes were then validated in an independent set of 210 patients matching the first set in terms of histology, stage, and clinical data.ResultsEleven genes with demonstrated prognostic value were selected from the literature. Complementary analyses in public databases and our own microarray dataset led to the investigation of six genes associated with good (BTG2, SELENBP1 and NFIB) or poor outcome (RRM1, EZH2 and FOXM1). In the first set of patients, EZH2 and RRM1 were significantly associated with better survival on top of age, sex and pathological stage (EZH2 p = 3.2e-02, RRM1 p = 5.9e-04). The prognostic values of EZH2 and RRM1 were not replicated in the second set of patients. A trend was observed for both genes in the joint analyses (n = 443) with higher expression associated with worse outcome.ConclusionAdenocarcinoma-specific mRNA expression levels of EZH2 and RRM1 are associated with poor post-surgical survival in the first set of patients, but not replicated in a clinically and pathologically matched independent validation set. This study highlights challenges associated with clinical translation of prognostic biomarkers.